Heart Failure-Related Cardiomyopathy
Peptides explored for heart failure and rare cardiomyopathies — elamipretide (FDA-approved 2025 for Barth syndrome), MOTS-c — with honest framing about narrow validated indications and where peptides fit alongside conventional heart failure therapy.
Heart failure is a clinical syndrome of impaired cardiac pumping or filling, affecting roughly 6 million US adults with rising incidence in aging populations. Subtypes include heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and various cardiomyopathies (dilated, hypertrophic, restrictive, infiltrative, mitochondrial). Modern HFrEF treatment is guideline-directed medical therapy ('quadruple therapy'): ARNI (sacubitril/valsartan) or ACE inhibitor/ARB, beta-blocker, mineralocorticoid receptor antagonist (spironolactone, eplerenone, finerenone), and SGLT2 inhibitor (empagliflozin, dapagliflozin) — with cardiovascular mortality reductions of 60-70% over decades of therapy compared to no treatment.
For specific cardiomyopathies, treatment is targeted: hypertrophic cardiomyopathy responds to mavacamten and aficamten (myosin inhibitors) plus traditional therapy; transthyretin amyloid cardiomyopathy responds to tafamidis; mitochondrial cardiomyopathies have limited targeted options historically.
Peptide therapy entered the heart failure landscape meaningfully in 2025 with the FDA approval of elamipretide (Forzinity, Stealth BioTherapeutics) for Barth syndrome — a rare X-linked mitochondrial cardiomyopathy in boys and young men with cardiolipin synthesis defects. Elamipretide is a small mitochondrial-targeted peptide that binds and stabilizes cardiolipin, restoring mitochondrial function. The approval was based on dedicated Phase 3 trials demonstrating cardiac and functional improvements.
Beyond Barth syndrome, peptide research continues in heart failure broadly. MOTS-c has preclinical cardiac protection evidence. Apelin agonists are in trials for heart failure. Elamipretide itself was investigated in multiple cardiac and renal indications beyond Barth, with mixed results in larger populations.
The honest framing: outside the narrow Barth syndrome indication, peptides do not substitute for guideline-directed heart failure therapy. This page covers what's actually known, where peptides have validated roles versus broader research interest, and important caveats. It is informational, not medical advice. Heart failure management requires cardiology specialty care.
Peptides discussed for Heart Failure-Related Cardiomyopathy
BNP
Natriuretic Peptide
An endogenous 32-amino-acid cardiac hormone secreted primarily by ventricular myocytes in response to wall stretch — the dominant natriuretic peptide in clinical practice and the basis of the BNP and NT-proBNP assays used worldwide for heart failure diagnosis, risk stratification, and management.
Elamipretide
Mitochondrial Peptide
The first FDA-approved mitochondria-targeted peptide. Stealth BioTherapeutics received accelerated approval in September 19, 2025 for Barth syndrome — a rare X-linked cardiolipin disorder affecting roughly 150 people in the US — marketed as Forzinity.
ANP
Natriuretic Peptide
An endogenous 28-amino-acid cardiac hormone secreted by atrial myocytes in response to wall stretch; drives natriuresis, vasodilation, and renin-aldosterone suppression. Approved in Japan as carperitide (recombinant human ANP) for acute decompensated heart failure since 1995, but never FDA-approved in the United States.
Apelin
Endogenous APJ Receptor Ligand
An endogenous peptide hormone and ligand of the APJ receptor with positive inotropic, vasodilatory, and insulin-sensitizing effects — heavily studied as a heart-failure target but not available as an approved therapy, with small-molecule APJ agonists now advancing through early clinical trials.
SS-31
Mitochondrial Peptide
A mitochondria-targeted cardiolipin-stabilizing tetrapeptide FDA-approved in September 2025 as Forzinity for Barth syndrome — the first approved mitochondria-targeted peptide — with ongoing trials in dry AMD, mitochondrial myopathy, and heart failure.
MOTS-c
Mitochondrial Peptide
A mitochondria-derived peptide that regulates metabolic homeostasis and has been called an 'exercise mimetic.'
How peptides target heart failure-related cardiomyopathy
Elamipretide (formerly SS-31) is the most clinically validated peptide in the cardiac space. As a mitochondrial-targeted peptide, it binds cardiolipin in the inner mitochondrial membrane, stabilizing the structure and function of the electron transport chain. The mechanism is particularly relevant to mitochondrial cardiomyopathies and conditions with mitochondrial dysfunction. The 2025 FDA approval for Barth syndrome was based on Phase 3 trial evidence demonstrating cardiac and functional improvements.
Beyond Barth syndrome, elamipretide has been investigated in primary mitochondrial myopathies, renal indications, and broader heart failure contexts with mixed results. The MMPOWER program in primary mitochondrial myopathy did not meet primary endpoints in larger Phase 3 trials, leading to FDA approval being limited to the Barth indication.
MOTS-c (the mitochondrial-derived peptide discussed broadly for longevity) has preclinical cardiac protection evidence in ischemia-reperfusion and cardiac aging models. Human cardiac trials are limited.
Apelin agonists target the apelin/APJ axis with vasodilatory, inotropic, and natriuretic effects relevant to heart failure. Multiple clinical programs are in development. None has reached approval for heart failure as of 2026.
BNP-pathway interventions discussed in the hypertension page (sacubitril in Entresto) have transformed heart failure treatment. Direct recombinant natriuretic peptide therapy (nesiritide) had limited success.
What peptides do not generally do for heart failure: replace guideline-directed quadruple therapy (ARNI/ACE/ARB + beta-blocker + MRA + SGLT2i); substitute for advanced heart failure therapy (mechanical circulatory support, transplant); modify the disease in HFpEF in any validated way at peptide-monotherapy level.
What the evidence shows
Elamipretide for Barth syndrome has Phase 3 evidence and FDA approval (2025), making it the most clinically validated peptide in the cardiac space. The TAZPOWER trial demonstrated cardiac functional improvements in this rare disease.
Elamipretide in broader cardiac and renal indications has more mixed evidence. Phase 3 in primary mitochondrial myopathy did not meet primary endpoints. Heart failure trials produced mixed results without leading to approval.
MOTS-c has preclinical cardiac evidence but no clinical trials specific to heart failure.
For evidence-validated heart failure therapy, the trial base is enormous. ARNI therapy (PARADIGM-HF). SGLT2 inhibitor therapy (DAPA-HF, EMPEROR-Reduced). Beta-blocker, MRA, and ACE inhibitor/ARB therapy. Mavacamten for obstructive hypertrophic cardiomyopathy. Tafamidis for transthyretin amyloid cardiomyopathy. Sacubitril/valsartan plus quadruple therapy is the foundation of modern HFrEF treatment.
Peptide therapy in heart failure outside the narrow Barth syndrome indication is largely investigational and does not displace guideline-directed therapy.
Important caveats
Heart failure management must be coordinated by cardiology — primary care management of heart failure is not adequate for most patients with HFrEF or significant HFpEF. The treatment hierarchy is well-established and saves lives. Patients should not discontinue guideline-directed therapy in favor of peptide protocols.
Elamipretide is FDA-approved specifically for Barth syndrome, not for general heart failure. Off-label use in other cardiac indications is not validated. The drug requires specialist coordination through Stealth BioTherapeutics' patient access programs.
Advanced heart failure therapy (mechanical circulatory support, transplant) is appropriate for selected patients with end-stage disease. Peptide therapy does not provide an alternative to these specialty interventions.
None of the other cardiac peptides discussed is FDA-approved for heart failure outside narrow indications. MOTS-c, apelin agonists, and other research peptides remain investigational.
Frequently asked questions
Is there a peptide approved for heart failure?
Elamipretide (Forzinity) is FDA-approved (2025) for Barth syndrome — a rare X-linked mitochondrial cardiomyopathy. It is not approved for general heart failure. Sacubitril (in combination with valsartan as Entresto) is a peptide-pathway drug (neprilysin inhibitor that prolongs endogenous natriuretic peptide activity) that is FDA-approved for heart failure. Other peptides remain investigational.
What is elamipretide and who can use it?
Elamipretide is a mitochondrial-targeted peptide that binds cardiolipin to stabilize mitochondrial structure and function. It is FDA-approved for Barth syndrome — a rare X-linked condition affecting boys and young men with cardiolipin synthesis defects, leading to cardiomyopathy, neutropenia, and skeletal myopathy. Approval is based on Phase 3 trial evidence showing cardiac improvements. Use is through specialty pharmacy programs.
Will MOTS-c help my heart failure?
There is no clinical evidence that MOTS-c treats heart failure in humans. Preclinical cardiac protection evidence in animal models exists. Patients with heart failure should focus on evidence-validated guideline-directed therapy (ARNI, beta-blocker, MRA, SGLT2 inhibitor) rather than research peptides without clinical validation.
Are peptides safer than ACE inhibitors for heart failure?
ACE inhibitors and ARBs (or ARNI in modern HFrEF treatment) have decades of evidence with substantial mortality reduction in heart failure. The 'safer' framing misses that untreated heart failure has very high mortality risk that exceeds the side-effect burden of evidence-validated therapy. Peptide therapy outside narrow validated indications does not provide comparable efficacy and is not 'safer' in any meaningful sense for general heart failure.
Can I take elamipretide for general heart failure?
Elamipretide is FDA-approved only for Barth syndrome. Off-label use in other cardiac indications is not validated by Phase 3 trial evidence — Phase 3 in primary mitochondrial myopathy did not meet primary endpoints, and broader heart failure trials produced mixed results. Patients with general heart failure should focus on guideline-directed therapy under cardiology coordination.
Part of these goals
Related conditions
Peptide families relevant to Heart Failure-Related Cardiomyopathy
Updated 2026-05-08